|Written by GSCR Staff|
|Wednesday, 20 July 2016 06:58|
In Monday’s Goldman Guide we discussed the disheartening chaos and violence all over the globe. Unfortunately, this amps of the finger pointing and blame game at both political conventions over the next two weeks which could lead to more anger and violence. We will step back. Healthcare is going nowhere, especially with the aging population here and globally in the industrialized world. We will look to this old guard today.
Harvard Biosciences, Inc. (NASDAQ – HBIO - $3.10) has been around for over 100 years and is a steady player in the small cap healthcare space. Below is the six month HBIO chart which highlights two important technical indicators. First, the stock has moved ahead of the 25-day EMA. Secondly, the stock has entered a rise from a trough in a head and shoulders patter over the last two months.
HBIO 6-Month Chart, 25 Day EMA
Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. The Company offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical products, infusion systems, microdialysis instruments, behavior research systems, isolated organ and tissue bath systems, and in vivo and in vitro electrophysiology recording, stimulation and analysis systems for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, TBSI, and HEKA brands. It also provides products for molecular biology labs comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific, AHN, and other brands. In addition, the Company offers spectrophotometers under the Libra, WPA, and BioDrop brands; microplate readers; amino acid analyzers; gel electrophoresis equipment under the Hoefer and Scie-Plas brands; and electroporation and electrofusion products, including systems and generators, electrodes, and accessories for research applications, such as in vivo, and in vitro gene delivery, cell fusion, and nuclear transfer cloning under the Harvard Apparatus BTX brand.
In keeping on the technical theme, HBIO currently has a short float of a super low 1.2%. On the fundamental side the 5-year PEG ratio is also a low 1.7. Additionally, Wall Street consensus has the revenue growing 38% over the next two years.
We believe HBIO is a solid short term play on a run to safety, i.e. the established. Look for a pop back to $4.00 over the next three months.
Have a great day!
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.
ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THISÂÂÂÂÂ ÂÂÂÂÂ INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com